 Interleukin-2
"Interleukin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
| Descriptor ID |
D007376
|
| MeSH Number(s) |
D12.644.276.374.465.021 D12.644.276.374.480.372 D12.776.467.374.465.021 D12.776.467.374.480.372 D23.529.374.465.155 D23.529.374.480.372
|
| Concept/Terms |
Interleukin-2- Interleukin-2
- Interleukin 2
- IL-2
- IL2
- TCGF
- Interleukine 2
- Lymphocyte Mitogenic Factor
- Mitogenic Factor, Lymphocyte
- T-Cell Growth Factor
- T Cell Growth Factor
- T-Cell Stimulating Factor
- T Cell Stimulating Factor
- Thymocyte Stimulating Factor
- Interleukin II
Ro-23-6019- Ro-23-6019
- Ro 23 6019
- Ro236019
- Ro-236019
- Ro 236019
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-2".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-2".
This graph shows the total number of publications written about "Interleukin-2" by people in this website by year, and whether "Interleukin-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 5 | 5 | 10 | | 1994 | 3 | 1 | 4 | | 1995 | 2 | 3 | 5 | | 1996 | 2 | 4 | 6 | | 1997 | 3 | 4 | 7 | | 1998 | 3 | 11 | 14 | | 1999 | 4 | 6 | 10 | | 2000 | 4 | 3 | 7 | | 2001 | 4 | 7 | 11 | | 2002 | 0 | 4 | 4 | | 2003 | 3 | 5 | 8 | | 2004 | 4 | 8 | 12 | | 2005 | 1 | 9 | 10 | | 2006 | 1 | 2 | 3 | | 2007 | 5 | 3 | 8 | | 2008 | 5 | 2 | 7 | | 2009 | 2 | 7 | 9 | | 2010 | 5 | 5 | 10 | | 2011 | 2 | 0 | 2 | | 2012 | 3 | 5 | 8 | | 2013 | 2 | 2 | 4 | | 2014 | 4 | 5 | 9 | | 2015 | 1 | 4 | 5 | | 2016 | 1 | 5 | 6 | | 2017 | 1 | 1 | 2 | | 2018 | 0 | 3 | 3 | | 2019 | 0 | 4 | 4 | | 2020 | 1 | 1 | 2 | | 2022 | 0 | 4 | 4 | | 2023 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-2" by people in Profiles.
-
Thompson B, Strange A, Amato CM, Hester-McCullough J, Sarnaik AA, Weber JS, Woods DM. CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy. J Immunol. 2023 09 01; 211(5):735-742.
-
Gadwa J, Amann M, Bickett TE, Knitz MW, Darragh LB, Piper M, Van Court B, Bukkapatnam S, Pham TT, Wang XJ, Saviola AJ, Deak LC, Uma?a P, Klein C, D'Alessandro A, Karam SD. Selective targeting of IL2R?? combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. Cell Rep Med. 2023 08 15; 4(8):101150.
-
Wang Z, Ma J, Zhang H, Ramakrishna R, Mintzlaff D, Mathes DW, Pomfret EA, Lucia MS, Gao D, Haverkos BM, Wang Z. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 07; 13(7):1309-1319.
-
Piper M, Hoen M, Darragh LB, Knitz MW, Nguyen D, Gadwa J, Durini G, Karakoc I, Grier A, Neupert B, Van Court B, Abdelazeem KNM, Yu J, Olimpo NA, Corbo S, Ross RB, Pham TT, Joshi M, Kedl RM, Saviola AJ, Amann M, Uma?a P, Codarri Deak L, Klein C, D'Alessandro A, Karam SD. Simultaneous targeting of PD-1 and IL-2R?? with radiation therapy inhibits pancreatic cancer growth and metastasis. Cancer Cell. 2023 05 08; 41(5):950-969.e6.
-
Ollerton MT, Folkvord JM, La Mantia A, Parry DA, Meditz AL, McCarter MD, D'Aquila RT, Connick E. Follicular regulatory T cells eliminate HIV-1-infected follicular helper T cells in an IL-2 concentration dependent manner. Front Immunol. 2022; 13:878273.
-
Johnson MJ, Liu C, Ghosh D, Lang N, Levin MJ, Weinberg A. Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence. J Infect Dis. 2022 04 19; 225(8):1477-1481.
-
Iguchi N, Hecht SL, Gao D, Wilcox DT, Malykhina AP, Cost NG. Sexual dimorphic impacts of systemic vincristine on lower urinary tract function. Sci Rep. 2022 03 24; 12(1):5113.
-
Eggermont AM, Ascierto PA, Khushalani NI, Schadendorf D, Boland G, Weber J, Lewis KD, Johnson D, Rivalland G, Khattak A, Majem M, Gogas H, Long GV, Currie SL, Chien D, Tagliaferri MA, Carlino MS, Diab A. PIVOT-12: a?phase III?study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncol. 2022 Mar; 18(8):903-913.
-
Dillon SM, Mickens KL, Thompson TA, Cooper EH, Nesladek S, Christians AJ, Castleman M, Guo K, Wood C, Frank DN, Kechris K, Santiago ML, Wilson CC. Granzyme B+ CD4 T cells accumulate in the colon during chronic HIV-1 infection. Gut Microbes. 2022 Jan-Dec; 14(1):2045852.
-
Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Nguyen T, Hoch U, Currie SL, Lin W, Tagliaferri MA, Zalevsky J, Sznol M, Hurwitz ME. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. J Clin Oncol. 2021 09 10; 39(26):2914-2925.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|